TY - JOUR
T1 - Pharmacogenetic Implementation Studies—Lessons Learned From the PREPARE Study
AU - Guchelaar, Henk Jan
AU - van der Wouden, Cathelijne H.
AU - Manson, Lisanne E.N.
AU - Abdullah-Koolmees, Heshu
AU - Blagec, Kathrin
AU - Blagus, Tanja
AU - Böhringer, Stefan
AU - Cecchin, Erika
AU - Cheung, Ka Chun
AU - Deneer, Vera H.M.
AU - Jonsson, Siv
AU - Joefield-Roka, Candace
AU - Just, Katja S.
AU - Karlsson, Mats O.
AU - Konta, Lidija
AU - Koopmann, Rudolf
AU - Kriek, Marjolein
AU - Lehr, Thorsten
AU - Mitropoulou, Christina
AU - Rollinson, Victoria
AU - Roncato, Rossana
AU - Samwald, Matthias
AU - Schaeffeler, Elke
AU - Skokou, Maria
AU - Schwab, Matthias
AU - Steinberger, Daniela
AU - Stingl, Julia C.
AU - Tremmel, Roman
AU - Turner, Richard M.
AU - van Rhenen, Mandy H.
AU - Dávila-Fajardo, Cristina L.
AU - Dolžan, Vita
AU - Patrinos, George P.
AU - Pirmohamed, Munir
AU - Sunder-Plassmann, Gere
AU - Toffoli, Giuseppe
AU - Swen, Jesse J.
N1 - Publisher Copyright:
© 2025 The Author(s). Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
PY - 2025/10
Y1 - 2025/10
N2 - The Ubiquitous Pharmacogenomics consortium (www.upgx.eu) has recently completed and published the Preemptive Pharmacogenomic Testing for Preventing Adverse Drug Reactions (PREPARE) study on the implementation of panel-based pharmacogenetic testing. PREPARE has provided interesting lessons for the design, execution, and interpretation of future clinical implementation studies. In this paper, we share our experience and lessons learned from the PREPARE study for future pharmacogenetic implementation studies. Issues addressed are the study population, intervention, endpoint, randomization, blinding, crossover, ethics, real-world changes during the study, and data analysis and reporting.
AB - The Ubiquitous Pharmacogenomics consortium (www.upgx.eu) has recently completed and published the Preemptive Pharmacogenomic Testing for Preventing Adverse Drug Reactions (PREPARE) study on the implementation of panel-based pharmacogenetic testing. PREPARE has provided interesting lessons for the design, execution, and interpretation of future clinical implementation studies. In this paper, we share our experience and lessons learned from the PREPARE study for future pharmacogenetic implementation studies. Issues addressed are the study population, intervention, endpoint, randomization, blinding, crossover, ethics, real-world changes during the study, and data analysis and reporting.
UR - https://www.scopus.com/pages/publications/105011163000
U2 - 10.1002/cpt.3749
DO - 10.1002/cpt.3749
M3 - Article
C2 - 40552566
AN - SCOPUS:105011163000
SN - 0009-9236
VL - 118
SP - 803
EP - 812
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 4
ER -